Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in:

Open Access 01-12-2017 | Research

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Authors: Brian M. Necela, Bianca C. Axenfeld, Daniel J. Serie, Jennifer M. Kachergus, Edith A. Perez, E. Aubrey Thompson, Nadine Norton

Published in: Clinical and Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On the basis that gene expression is known to be altered in multiple models of heart failure, we examined differential gene expression of iPSC-derived cardiomyocytes treated at day 11 with the ERBB2 targeted monoclonal antibody, trastuzumab for 48 h and the small molecule tyrosine kinase inhibitor of EGFR and ERBB2.

Results

Transcriptome sequencing was performed on four replicates from each group (48 h untreated, 48 h trastuzumab and 48 h lapatinib) and differential gene expression analyses were performed on each treatment group relative to untreated cardiomyocytes. 517 and 1358 genes were differentially expressed, p < 0.05, respectively in cardiomyocytes treated with trastuzumab and lapatinib. Gene ontology analyses revealed in cardiomyocytes treated with trastuzumab, significant down-regulation of genes involved in small molecule metabolism (p = 3.22 × 10−9) and cholesterol (p = 0.01) and sterol (p = 0.03) processing. We next measured glucose uptake and lactate production in iPSC-derived cardiomyocytes 13 days post-plating, treated with trastuzumab up to 96 h. We observed significantly decreased glucose uptake from the media of iPSC-derived cardiomyocytes treated with trastuzumab as early as 24 h (p = 0.001) and consistently up to 96 h (p = 0.03).

Conclusions

Our study suggests dysregulation of cardiac gene expression and metabolism as key elements of ERBB2 signaling that could potentially be early biomarkers of cardiotoxicity.
Appendix
Available only for authorised users
Literature
1.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 344(11):783–792CrossRefPubMed
2.
Fried G, Regev T, Moskovitz M (2013) Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat 142(1):1–7CrossRefPubMed
3.
Montserrat M, Leveque D, Barthelemy P, Bergerat JP (2012) Duration of adjuvant trastuzumab treatment in routine practice. Anticancer Res 32(10):4585–4588PubMed
4.
Murray LJ, Ramakrishnan S, O’Toole L, Manifold IH, Purohit OP, Coleman RE (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast. 19(5):339–344CrossRefPubMed
5.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefPubMed
6.
Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, Banach M (2012) Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2—a prospective study. Arch Med Sci. 8(2):227–235CrossRefPubMedPubMedCentral
7.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684CrossRefPubMed
8.
Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134CrossRefPubMed
9.
Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 18(2):113–119CrossRefPubMed
10.
Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P (2012) Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer 106(1):32–38CrossRefPubMed
11.
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP et al (2014) Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat 146(2):411–419CrossRefPubMed
12.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 15(10):1063–1093CrossRefPubMedPubMedCentral
13.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911–939CrossRefPubMed
14.
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459–465CrossRefPubMed
15.
Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1–12CrossRefPubMed
16.
ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS et al (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE 8(11):e79543CrossRefPubMedPubMedCentral
17.
Liu L, Zhu J, Glass PS, Brink PR, Rampil IJ, Rebecchi MJ (2009) Age-associated changes in cardiac gene expression after preconditioning. Anesthesiology 111(5):1052–1064CrossRefPubMed
18.
Reischauer S, Arnaout R, Ramadass R, Stainier D (2014) Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture. Circ Res 115(10):845–856CrossRefPubMedPubMedCentral
19.
Reischauer S, Levesque MP, Nusslein-Volhard C, Sonawane M (2009) Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis. PLoS Genet 5(11):e1000720CrossRefPubMedPubMedCentral
20.
Aggarwal P, Turner A, Matter A, Kattman SJ, Stoddard A, Lorier R et al (2014) RNA expression profiling of human iPSC-derived cardiomyocytes in a cardiac hypertrophy model. PLoS ONE 9(9):e108051CrossRefPubMedPubMedCentral
21.
Heidecker B, Lamirault G, Kasper EK, Wittstein IS, Champion HC, Breton E et al (2010) The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. Eur Heart J 31(10):1188–1196CrossRefPubMed
22.
Kittleson MM, Hare JM (2005) Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy. Future Cardiol. 1(6):793–808CrossRefPubMed
23.
Kittleson MM, Hare JM (2005) Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med 15(4):130–138CrossRefPubMed
24.
Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E et al (2005) Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genom 21(3):299–307CrossRef
25.
Kittleson MM, Ye SQ, Irizarry RA, Minhas KM, Edness G, Conte JV et al (2004) Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 110(22):3444–3451CrossRefPubMed
26.
Treish I, Schwartz R, Lindley C (2000) Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health-Syst Ph. 57(22):2063–2076
27.
Zhu S, Cawley SM, Bloch KD, Huang PL (2013) Trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes. Cardiovasc Sys 1:10CrossRef
28.
Kalari KR, Nair AA, Bhavsar JD, O’Brien DR, Davila JI, Bockol MA et al (2014) MAP-RSeq: mayo analysis pipeline for RNA sequencing. BMC Bioinform 15:224CrossRef
29.
Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313(4):856–862CrossRefPubMed
30.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402–408CrossRefPubMed
31.
Gene Ontology Consortium (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43((Database issue)):1049–1056CrossRef
32.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25(1):25–29CrossRefPubMedPubMedCentral
33.
Opel A, Nobles M, Montaigne D, Finlay M, Anderson N, Breckenridge R et al (2015) Absence of the regulator of G-protein signalling, RGS4, predisposes to atrial fibrillation and is associated with abnormal calcium handling. J Biol Chem 290(31):19233–19244CrossRefPubMedPubMedCentral
34.
Tokudome T, Kishimoto I, Horio T, Arai Y, Schwenke DO, Hino J et al (2008) Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 117(18):2329–2339CrossRefPubMed
35.
Xu YJ, Arneja AS, Tappia PS, Dhalla NS (2008) The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol. 13(2):57–65PubMedPubMedCentral
36.
Ito T, Kimura Y, Uozumi Y, Takai M, Muraoka S, Matsuda T et al (2008) Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44(5):927–937CrossRefPubMed
37.
Ito T, Yoshikawa N, Ito H, Schaffer SW (2015) Impact of taurine depletion on glucose control and insulin secretion in mice. J Pharmacol Sci. 129(1):59–64CrossRefPubMed
38.
Perry MC, Dufour CR, Eichner LJ, Tsang DW, Deblois G, Muller WJ et al (2014) ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction. Mol Cell Biol 34(23):4232–4243CrossRefPubMedPubMedCentral
39.
Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15(12):5268–5282CrossRefPubMedPubMedCentral
40.
De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106(1):35–46CrossRefPubMed
41.
42.
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS et al (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5):429–440CrossRefPubMed
43.
Donovan N, Crown JP, Clynes M (2006) Dual targeting of EGFR and HER-2 in breast cancer cell lines. J Clin Oncol 24(18_suppl):13132
44.
Barth AS, Zhang Y, Li T, Smith RR, Chimenti I, Terrovitis I et al (2012) Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl Med. 1(4):289–297CrossRefPubMedPubMedCentral
45.
Kolwicz SC Jr, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 113(5):603–616CrossRefPubMed
46.
Sugden MC, Bulmer K, Holness MJ (2001) Fuel-sensing mechanisms integrating lipid and carbohydrate utilization. Biochem Soc Trans 29(Pt 2):272–278CrossRefPubMed
47.
Sugden MC, Holness MJ (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 284(5):E855–E862CrossRefPubMed
48.
Piao L, Marsboom G, Archer SL (2010) Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl). 88(10):1011–1020CrossRefPubMedPubMedCentral
49.
Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT et al (2010) The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl). 88(1):47–60CrossRefPubMed
50.
Churchill EN, Murriel CL, Chen CH, Mochly-Rosen D, Szweda LI (2005) Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ Res 97(1):78–85CrossRefPubMed
51.
Kudej RK, White LT, Kudej AB, Vatner SF, Lewandowski ED (2002) Brief increase in carbohydrate oxidation after reperfusion reverses myocardial stunning in conscious pigs. Circulation 106(22):2836–2841CrossRefPubMed
52.
Lewandowski ED, White LT (1995) Pyruvate dehydrogenase influences postischemic heart function. Circulation 91(7):2071–2079CrossRefPubMed
53.
McVeigh JJ, Lopaschuk GD (1990) Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 259(4 Pt 2):H1079–H1085PubMed
Metadata
Title
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
Authors
Brian M. Necela
Bianca C. Axenfeld
Daniel J. Serie
Jennifer M. Kachergus
Edith A. Perez
E. Aubrey Thompson
Nadine Norton
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2017
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-016-0133-2

Other articles of this Issue 1/2017

Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients

  • Open Access
  • Research

Using single-cell multiple omics approaches to resolve tumor heterogeneity

  • Open Access
  • Review

Proteomics in asthma: the clinicians were right after all, were not they?

  • Open Access
  • Commentary

CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study

  • Open Access
  • Research

Expression of Concern to: Role of physiotherapy in the mobilization of patients with spinal cord injury undergoing human embryonic stem cells transplantation

  • Open Access
  • Erratum

Translational research in pediatric pulmonary disease, 2017

  • Open Access
  • Perspective